Overview

In Vitro Diagnostics (IVD) Quality Control Market is poised to value USD 1552.33 million by 2028 end at a CAGR of 5.3% during the forecast period 2022 to 2028.

FutureWise Market Research has instantiated a report that provides an intricate analysis of In Vitro Diagnostics (IVD) Quality Control Market trend that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the In Vitro Diagnostics (IVD) Quality Control Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the In Vitro Diagnostics (IVD) Quality Control Market:
• Bio-Rad Laboratories Inc.
• Randox Laboratories Ltd.
• Thermo Fisher Scientific Inc.
• Technopath Clinical Diagnostics.
• Bio-Techne Corporation
• Fortress Diagnostics.
• Roche Diagnostics
• Siemens Healthineers
• Danaher Corporation
• SeraCare Life Sciences Inc.
• Abbott Laboratories Inc.
• Sysmex Corporation
• Ortho-Clinical
• Helena Laboratories
(Note: The list of the major players will be updated with the latest market scenario and trends)

In Vitro Diagnostics (IVD) Quality Control Market Segmentation:
By Product Type
• Quality Control Products
    o Serum/Plasma-Based Controls
    o Whole Blood-Based Controls
    o Urine Based Controls
• Data Management Solutions
• Quality Assurance Services
By Application
• Immunochemistry/Immunoassay
• Clinical Chemistry
• Hematology
• Molecular Diagnostics
• Coagulation & Hemostatis
• Microbiology
By Manufacturer
• Third-Party Control Manufacturers
    o Independent Controls
    o Instrument-Specific Controls
• Original Equipment Manufacturers
By End User
• Clinical Laboratories
• Hospitals
• Academic & Research Institutes
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the In Vitro Diagnostics (IVD) Quality Control Market By Product Type, By Manufacturer, By Application, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customisation offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global In Vitro Diagnostics (IVD) Quality Control Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Product Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global In Vitro Diagnostics (IVD) Quality Control Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Product Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Product Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. In Vitro Diagnostics (IVD) Quality Control Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million)
  7.1. Quality Control Products
  7.1.1. Serum/Plasma-Based Controls
  7.1.2. Whole Blood-Based Controls
  7.1.3. Urine-Based Controls
  7.2. Data Management Solutions
  7.3. Quality Assurance Services

8. In Vitro Diagnostics (IVD) Quality Control Market, By Manufacturer Historical Analysis and Forecast 2022-2028 (USD Million)  
  8.1. Immunochemistry/Immunoassay
  8.2. Clinical Chemistry
  8.3. Hematology
  8.4. Molecular Diagnostics
  8.5. Coagulation & Hemostatis
  8.6. Microbiology

9. In Vitro Diagnostics (IVD) Quality Control Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million)  
  9.1. Third-Party Control Manufacturers
      9.1.1. Independent Controls
      9.1.2. Instrument-Specific Controls
  9.2. Original Equipment Manufacturers

10. In Vitro Diagnostics (IVD) Quality Control Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)  
  10.1. Clinical Laboratories
  10.2. Hospitals
  10.3. Academic & Research Institutes

11. North America In Vitro Diagnostics (IVD) Quality Control Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. U.S.A
          11.2.2. Canada
          11.2.3. Mexico
    11.3. Market Size (USD Million) Forecast for North America 2022-2028

12. Latin America In Vitro Diagnostics (IVD) Quality Control Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Brazil
          12.2.2. Venezuela
          12.2.3. Argentina
          12.2.4. Rest of Latin America
    12.3. Market Size (USD Million) Forecast for Latin America 2022-2028

13. Europe In Vitro Diagnostics (IVD) Quality Control Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Germany
          13.2.2. U.K         
          13.2.3. France
          13.2.4. Italy
          13.2.5. Spain
          13.2.6. Russia
          13.2.7. Poland
          13.2.8. Rest of Europe
    13.3. Market Size (USD Million) Forecast for Europe 2022-2028

14. Asia Pacific In Vitro Diagnostics (IVD) Quality Control Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Japan
          14.2.2. China
          14.2.3. India
          14.2.4. Australia and New Zealand
          14.2.5. ASEAN
          14.2.6. Rest of Asia Pacific
    14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          15.2.1. GCC
          15.2.2. Israel
          15.2.3. South Africa
          15.2.4. Rest of MEA
    15.3. Market Size (USD Million) Forecast for MEA 2022-2028

16. Market Share Analysis and Competitive Landscape   
    16.1. Global Landscape - Key Players, Revenue and Presence
    16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    16.3. Global Emerging Companies
    16.4. North America - Market Share Analysis and Key Regional Players
    16.5. Europe - Market Share Analysis and Key Regional Players
    16.6. Asia Pacific - Market Share Analysis and Key Regional Players
    16.7. Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   17.1. Bio-Rad Laboratories Inc.
         17.1.1. Company Overview
         17.1.2. Product Portfolio
         17.1.3. SWOT Analysis
         17.1.4. Financial Overview
         17.1.5. Strategic Overview
   17.2.Randox Laboratories Ltd.
         17.2.1. Company Overview
         17.2.2. Product Portfolio
         17.2.3. SWOT Analysis
         17.2.4. Financial Overview
         17.2.5. Strategic Overview
   17.3. Thermo Fisher Scientific Inc.
         17.3.1. Company Overview
         17.3.2. Product Portfolio
         17.3.3. SWOT Analysis
         17.3.4. Financial Overview
         17.3.5. Strategic Overview
   17.4. Technopath Clinical Diagnostics.
         17.4.1. Company Overview
         17.4.2. Product Portfolio
         17.4.3. SWOT Analysis
         17.4.4. Financial Overview
         17.4.5. Strategic Overview
   17.5. Bio-Techne Corporation
         17.5.1. Company Overview
         17.5.2. Product Portfolio
         17.5.3. SWOT Analysis
         17.5.4. Financial Overview
         17.5.5. Strategic Overview          
   17.6. Fortress Diagnostics.
         17.6.1. Company Overview
         17.6.2. Product Portfolio
         17.6.3. SWOT Analysis
         17.6.4. Financial Overview
         17.6.5. Strategic Overview      
   17.7. Roche Diagnostics,
         17.7.1. Company Overview
         17.7.2. Product Portfolio
         17.7.3. SWOT Analysis
         17.7.4. Financial Overview
         17.7.5. Strategic Overview
   17.8. Siemens Healthineers
         17.8.1. Company Overview
         17.8.2. Product Portfolio
         17.8.3. SWOT Analysis
         17.8.4. Financial Overview
         17.8.5. Strategic Overview
   17.9. Danaher Corporation
         17.9.1. Company Overview
         17.9.2. Product Portfolio
         17.9.3. SWOT Analysis
         17.9.4. Financial Overview
         17.9.5. Strategic Overview
   17.10. SeraCare Life Sciences Inc.
         17.10.1. Company Overview
         17.10.2. Product Portfolio
         17.10.3. SWOT Analysis
         17.10.4. Financial Overview
         17.10.5. Strategic Overview
   17.11. Abbott Laboratories Inc.
         17.11.1. Company Overview
         17.11.2. Product Portfolio
         17.11.3. SWOT Analysis
         17.11.4. Financial Overview
         17.11.5. Strategic Overview
   17.12. Sysmex Corporation
         17.12.1. Company Overview
         17.12.2. Product Portfolio
         17.12.3. SWOT Analysis
         17.12.4. Financial Overview
         17.12.5. Strategic Overview
   17.13. Ortho-Clinical
         17.13.1. Company Overview
         17.13.2. Product Portfolio
         17.13.3. SWOT Analysis
         17.13.4. Financial Overview
         17.13.5. Strategic Overview
   17.14. Helena Laboratories
         17.14.1. Company Overview
         17.14.2. Product Portfolio
         17.14.3. SWOT Analysis
         17.14.4. Financial Overview
         17.14.5. Strategic Overview

18. Pre and Post COVID-19 Impact
   18.1. Positive influence on the healthcare industry
   18.2. The financial disruption of the manufacturing sector
   18.3. Impact of COVID-19 on emerging companies
   18.4. Significant mandates in the healthcare regulations initiated by administrations
   18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client

Tables

Figures